CytoDyn Submits Dose Justification Report to FDA to Begin Overcoming Deficiencies in its BLA for HIV
VANCOUVER, Washington, July 01, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results